And on it goes

Not like we needed any additional evidence that CGM has become the standard for glucose measurement but check this out

“One Drop, a leader in precision health solutions for people living with chronic conditions, today announced Carrie Siragusa, CPA, as VP of Commercial Strategy. Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.”

Now there are several interesting tidbits in that one paragraph – first OneDrop is now a . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

Fix it, sell it or pass it on

When a large company has a problem with a unit they basically have three choices. They can either fix it, sell it or make it someone else’s problem by passing it on. Our friends at Medtronic have attempted to fix the problems they themselves created for their diabetes unit. Since that has failed they are now taking steps to make the unit sellable. Step one in this process is taking place as we speak as the unit has begun downsizing via layoffs and restructuring.

As we have noted for some time now the issue for Medtronic is finding a . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

Nothing new here

There are times we sit back and wonder what all the fuss is about. We’ve been having these moments a lot lately especially in the digital/virtual health market. And not to get off track should we not come up with a new term that encompasses digital/virtual into one phrase perhaps maybe disease management with new technology or is that too old school. But things are pretty much playing out as we expected here.

We have reached the consolidation phase where those who didn’t have a comprehensive platform are acquiring what they need. Carbon Health acquiring Steady . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

A sign of things to come?

Before we get into business a little shameless self-promotion but self-promotion for some very worthy organizations. Some of you are aware of my past efforts at raising money while doing a triathlon. This year given I haven’t been able to race because of Covid I decided to do something a little different. First I am raising money for THREE charities – Beyond Type 1 – Homeless Veterans in San Diego and Prostate Cancer Research – but wait there’s more – I’ve given the race a name – Doing It Three Ways and today I am pleased to launch . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

The Rules

Ok we’re getting just a little irked at all these CGM, OmniPod and Tyler wannabes. So in an effort to separate the real from the imagined we have created some rules for these companies. See we get lots of inquiries from these start up toy companies most of whom that don’t stand an ice cubes chance in hell of ever becoming a commercially viable toy company. Yet each one has a great PowerPoint, most have a well-designed web site, nearly all have a very active social media presence (guess the days of being in stealth mode are . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

What matters, what doesn’t

When it comes to the toys in the toy chest there is no better conference than ATTD and while virtual this year once again the diabetes device world is going gaga this week. Dexcom revealed more details about the G7, Medtronic released more data on hybrid closed loop and Senseonics data on their longer term sensor. As valuable as this information may be the question is does it matter all that much or perhaps put another way will it change the dynamics of the diabetes device landscape.

Our answer is no. Is the G7 the Libre killer . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

Does it matter?

One day someone will have to explain to us how a company that once dominated a market only to screw it up because of their own arrogance should be given the benefit of the doubt. This is basically what Medtronic is asking investors to do when it comes to their still struggling diabetes unit. They want to be given yet another chance as this is not the first not even the second time this unit is in the midst of a turnaround. Keep in mind we’ve been covering MiniMed since we started writing Diabetic Investor.

Looking at the . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

News, notes and other things

While the FDA continues to deal with the backlog created by Covid things in Europe seem to be moving a bit quicker. Today Medtronic announced they have obtained CE marks for their Guardian 4 sensor plus expanded functionality for their InPen system. Per a company issued press release;

“Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced CE (Conformité Européenne) Mark for expanded functionality of the company's InPen™ smart2 insulin pen for multiple daily injections (MDI). The company also announced CE Mark for its Guardian™ 4 sensor3, which requires no fingersticks1 for calibration . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

Next Steps and they are NOT obvious

Every once in a while a drug comes along that seems to have blockbuster written all over it. In the case of tirzepatide from Lilly we’d even go as far as mega-blockbuster. To say that tirzepatide is widely anticipated is like saying people are looking forward to summer.

Now that the drug has completed its extensive clinical program and is set to be submitted to the FDA a complex set of choices faces not just Lilly but also Novo Nordisk who must deal with the impact of this new widely anticipated drug which we should be easily approved . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

Just what is it?

The diabetes device sector in some respects isn’t all that complex. As one former executive said there are three things you need to be successful. Can you build it, can you sell and support it and most importantly of all can you get it paid for. Traditionally making money is also pretty simple as once approved and on formulary device makers aren’t paid by the patient but the patients’ health insurance provider. The hard part is getting on formulary and navigating the complex maze of payors, PBM’s, etc.

Selling these devices also isn’t that complex as . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

© 2005 - 2021 Diabetic Investor, Inc., all rights reserved. Unless expressly permitted under your written license agreement, you are not authorized to forward or to otherwise copy our newsletter, or any portion thereof, by electronic means or otherwise. 17 U.S.C. §504 provides for statutory damages of up to $150,000 per infringement of a copyright and additional damages.